MX345042B - Composiciones y métodos para tratamiento no quirúrgico de ptosis. - Google Patents
Composiciones y métodos para tratamiento no quirúrgico de ptosis.Info
- Publication number
- MX345042B MX345042B MX2013009597A MX2013009597A MX345042B MX 345042 B MX345042 B MX 345042B MX 2013009597 A MX2013009597 A MX 2013009597A MX 2013009597 A MX2013009597 A MX 2013009597A MX 345042 B MX345042 B MX 345042B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- oxymetazoline
- ptosis
- methods
- surgical treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 206010015995 Eyelid ptosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000003004 ptosis Diseases 0.000 title abstract 3
- 238000012148 non-surgical treatment Methods 0.000 title abstract 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 abstract 8
- 229960001528 oxymetazoline Drugs 0.000 abstract 4
- 208000006550 Mydriasis Diseases 0.000 abstract 2
- 229960001802 phenylephrine Drugs 0.000 abstract 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 238000011200 topical administration Methods 0.000 abstract 2
- 230000001010 compromised effect Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000010339 dilation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001179 pupillary effect Effects 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
- B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448949P | 2011-03-03 | 2011-03-03 | |
| US13/218,584 US20120225918A1 (en) | 2011-03-03 | 2011-08-26 | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| US13/270,577 US8357714B2 (en) | 2011-03-03 | 2011-10-11 | Compositions and methods for non-surgical treatment of ptosis |
| PCT/US2012/026496 WO2012118704A1 (en) | 2011-03-03 | 2012-02-24 | Compositions and methods for non-surgical treatment of ptosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013009597A MX2013009597A (es) | 2014-01-08 |
| MX345042B true MX345042B (es) | 2017-01-16 |
Family
ID=46753678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009597A MX345042B (es) | 2011-03-03 | 2012-02-24 | Composiciones y métodos para tratamiento no quirúrgico de ptosis. |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US20120225918A1 (enExample) |
| EP (2) | EP3653205A3 (enExample) |
| JP (1) | JP6106100B2 (enExample) |
| KR (1) | KR101889392B1 (enExample) |
| CN (1) | CN103501771B (enExample) |
| AU (1) | AU2012223615B2 (enExample) |
| BR (1) | BR112013022094A2 (enExample) |
| CA (1) | CA2827285C (enExample) |
| CY (1) | CY1122565T1 (enExample) |
| DK (1) | DK2680829T3 (enExample) |
| ES (1) | ES2750123T3 (enExample) |
| HR (1) | HRP20192266T1 (enExample) |
| HU (1) | HUE046740T2 (enExample) |
| LT (1) | LT2680829T (enExample) |
| MX (1) | MX345042B (enExample) |
| PL (1) | PL2680829T3 (enExample) |
| PT (1) | PT2680829T (enExample) |
| RS (1) | RS59636B1 (enExample) |
| RU (1) | RU2582392C2 (enExample) |
| SG (1) | SG192801A1 (enExample) |
| SI (1) | SI2680829T1 (enExample) |
| SM (1) | SMT201900718T1 (enExample) |
| WO (1) | WO2012118704A1 (enExample) |
| ZA (1) | ZA201307262B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| BR112014006607A2 (pt) | 2011-09-20 | 2017-04-25 | Allergan Inc | composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| CA2869060A1 (en) * | 2014-07-28 | 2016-01-28 | Queen's University At Kingston | Dosage forms and methods for diagnosing sympathetic nervous system dysfunction |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CN115006537A (zh) | 2016-01-26 | 2022-09-06 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
| CN106726115B (zh) * | 2016-12-22 | 2023-01-20 | 上海交通大学医学院附属第九人民医院 | 一种眼睑功能矫正器 |
| CN106938039A (zh) * | 2017-03-29 | 2017-07-11 | 卢仁华 | 眼睑下垂的治疗药物 |
| WO2019204401A1 (en) * | 2018-04-19 | 2019-10-24 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| CN108635434A (zh) * | 2018-06-24 | 2018-10-12 | 吴安相 | 一种治疗眼睑下垂的侗族中药配方 |
| SG11202104410SA (en) * | 2018-11-26 | 2021-06-29 | Cellix Bio Private Ltd | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| AU2021259787A1 (en) * | 2020-04-23 | 2022-12-22 | Okogen, Inc. | Treatment of viral conjunctivitis |
| US20240156786A1 (en) | 2021-03-03 | 2024-05-16 | Voom, Llc | Compositions and methods for treatment of blepharitis |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1117588B (de) | 1960-09-30 | 1961-11-23 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates |
| US3670087A (en) * | 1970-10-16 | 1972-06-13 | Miles Lab | Method of lowering intraocular pressure |
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| DE3227741A1 (de) | 1982-07-24 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung |
| FR2549015B1 (fr) * | 1983-07-13 | 1986-06-13 | Oreal | Ensemble compte-gouttes |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| WO1998047510A1 (en) * | 1997-04-24 | 1998-10-29 | Taisho Pharmaceutical Co., Ltd. | Eye drops |
| EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| US5885550A (en) * | 1998-07-02 | 1999-03-23 | Vallier; Deandra K. | Ophthalmic whitening solution |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
| AU2001291159A1 (en) * | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| JP2004509920A (ja) * | 2000-09-29 | 2004-04-02 | ボード オブ トラスティーズ オペレーティング ミシガン ステート ユニヴァーシティ | カテコールアミン医薬組成物および方法 |
| US7780976B2 (en) * | 2002-05-30 | 2010-08-24 | Eye Care And Cure, Asia | Apparatus and method for delivering controlled quantities of one or more agents to the eye |
| EP1517673A1 (en) * | 2002-06-20 | 2005-03-30 | Novartis Consumer Health S.A. | Nasal composition comprising a mucopolysaccharide and propylene glycol |
| US6806364B2 (en) | 2002-07-29 | 2004-10-19 | Ast Products, Inc. | Ophthalmic compositions |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US7022740B2 (en) | 2004-04-29 | 2006-04-04 | Leonard Mackles | Lubricious ophthalmic solutions |
| US7618615B2 (en) * | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| JP4942328B2 (ja) * | 2004-11-01 | 2012-05-30 | ロート製薬株式会社 | ビタミンｂ６類含有水性組成物 |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| JP4956981B2 (ja) * | 2005-01-05 | 2012-06-20 | 大正製薬株式会社 | オキシメタゾリン含有水性組成物 |
| TWI454286B (zh) | 2006-03-17 | 2014-10-01 | Johnson & Johnson Vision Care | 安定氧化性不安定組合物之方法 |
| CA2650592A1 (en) | 2006-04-26 | 2007-11-08 | Aciex, Inc. | Compositions for the treatment and prevention of eyelid swelling |
| US8466203B2 (en) | 2006-12-06 | 2013-06-18 | David Choohyun Paik | Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds |
| MX2010005012A (es) * | 2007-11-08 | 2010-06-23 | Aciex Therapeutics Inc | Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor. |
| EP3943069B1 (en) * | 2009-03-17 | 2024-11-27 | Nicox Ophthalmics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| CA2764477A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations, methods of manufacture, and methods of using same |
| US20130190317A1 (en) | 2010-08-06 | 2013-07-25 | Galderma Research & Development Snc | Combination of compounds for treating or preventing skin diseases |
| CA2819633C (en) | 2010-12-03 | 2019-04-23 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| AU2012217858A1 (en) * | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| JP2015518006A (ja) | 2012-05-25 | 2015-06-25 | エクスクリア インコーポレイテッド | キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| WO2015191917A1 (en) | 2014-06-11 | 2015-12-17 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CN115006537A (zh) | 2016-01-26 | 2022-09-06 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
-
2011
- 2011-08-26 US US13/218,584 patent/US20120225918A1/en not_active Abandoned
- 2011-10-11 US US13/270,577 patent/US8357714B2/en active Active
-
2012
- 2012-02-24 SM SM20190718T patent/SMT201900718T1/it unknown
- 2012-02-24 HU HUE12709421A patent/HUE046740T2/hu unknown
- 2012-02-24 BR BR112013022094A patent/BR112013022094A2/pt not_active Application Discontinuation
- 2012-02-24 SI SI201231705T patent/SI2680829T1/sl unknown
- 2012-02-24 EP EP19199263.5A patent/EP3653205A3/en active Pending
- 2012-02-24 DK DK12709421T patent/DK2680829T3/da active
- 2012-02-24 RU RU2013142602/15A patent/RU2582392C2/ru active
- 2012-02-24 AU AU2012223615A patent/AU2012223615B2/en active Active
- 2012-02-24 JP JP2013556744A patent/JP6106100B2/ja active Active
- 2012-02-24 RS RS20191580A patent/RS59636B1/sr unknown
- 2012-02-24 EP EP12709421.7A patent/EP2680829B1/en active Active
- 2012-02-24 KR KR1020137026050A patent/KR101889392B1/ko active Active
- 2012-02-24 MX MX2013009597A patent/MX345042B/es active IP Right Grant
- 2012-02-24 SG SG2013062245A patent/SG192801A1/en unknown
- 2012-02-24 WO PCT/US2012/026496 patent/WO2012118704A1/en not_active Ceased
- 2012-02-24 ES ES12709421T patent/ES2750123T3/es active Active
- 2012-02-24 PL PL12709421T patent/PL2680829T3/pl unknown
- 2012-02-24 LT LTEP12709421.7T patent/LT2680829T/lt unknown
- 2012-02-24 PT PT127094217T patent/PT2680829T/pt unknown
- 2012-02-24 CA CA2827285A patent/CA2827285C/en active Active
- 2012-02-24 CN CN201280011433.6A patent/CN103501771B/zh active Active
- 2012-02-24 HR HRP20192266TT patent/HRP20192266T1/hr unknown
- 2012-02-29 US US13/408,364 patent/US9018240B2/en active Active
-
2013
- 2013-09-27 ZA ZA2013/07262A patent/ZA201307262B/en unknown
-
2015
- 2015-02-18 US US14/625,099 patent/US9867808B2/en active Active
-
2017
- 2017-12-11 US US15/837,325 patent/US20180338953A1/en not_active Abandoned
-
2019
- 2019-09-20 US US16/577,262 patent/US10912765B2/en active Active
- 2019-11-07 CY CY20191101170T patent/CY1122565T1/el unknown
-
2020
- 2020-06-04 US US16/892,645 patent/US20200360345A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/679,278 patent/US20220218669A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345042B (es) | Composiciones y métodos para tratamiento no quirúrgico de ptosis. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| IN2014DN09434A (enExample) | ||
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| MX368876B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
| PH12015501538A1 (en) | Topical ocular analgesic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |